James Bradner

James E.
Bradner was the founder of Acetylon Pharmaceuticals, Inc. (2008) where the title held was Director; TetraLogic Research & Development Corp.
(2008) where the title held was Director; Tensha Therapeutics, Inc. (2011); Syros Pharmaceuticals, Inc. (2011) where the title held was Director from 2011 to 2015; and C4 Therapeutics, Inc. (2015).
Current jobs include Chief Executive Officer at Onyx Pharmaceuticals, Inc., ChemoCentryx, Inc., Five Prime Therapeutics, Inc., and TeneoBio, Inc.; Chairman at Novartis Institute for Functional Genomics, Inc.; Director at Foundation for the National Institutes of Health, Inc. since 2023; Executive VP-Research & Development at Amgen, Inc. since 2024; Associate Professor at Harvard Medical School; and Advisor at Longwood Fund Management LLC.
Former jobs include Associate Director-Therapeutics Science Centre at The Broad Institute, Inc.; Member-Supervisory Board at QIAGEN NV in 2015; Member of the American Chemical Society; Member of the American Society of Hematology; and President at Novartis Institutes for Biomedical Research, Inc. from 2016 to 2022.
Education includes an undergraduate degree from Harvard University conferred in 1994 and a doctorate from Pritzker School of Medicine.